UK markets close in 43 minutes

Gerresheimer AG (GRRMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
103.290.00 (0.00%)
As of 9:59AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close103.29
Open103.29
BidN/A x N/A
AskN/A x N/A
Day's range103.29 - 103.29
52-week range103.15 - 118.07
Volume25
Avg. volume0
Market cap3.243B
Beta (5Y monthly)1.00
PE ratio (TTM)33.05
EPS (TTM)3.12
Earnings dateN/A
Forward dividend & yield1.51 (1.47%)
Ex-dividend date10 Jun 2021
1y target estN/A
  • EQS Group

    Gerresheimer AG: Gerresheimer on growth course

    DGAP-News: Gerresheimer AG / Key word(s): Quarter Results/9 Month figures12.10.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Core business revenue shows third-quarter organic growth of 9.8 % Strategic positioning as innovative provider of biotech, pharma and beauty solutions delivers results Adjusted EBITDA margin in core business organically at 20.9 % in third quarter Third-quarter adjusted earnings per share rise organically by 5.2 % Guidance confirmed for

  • EQS Group

    Gerresheimer AG: Continuity on the Management Board: Gerresheimer extends contract with CFO Dr. Bernd Metzner ahead of schedule by a further five years

    DGAP-News: Gerresheimer AG / Key word(s): Personnel/Contract09.09.2021 / 09:00 The issuer is solely responsible for the content of this announcement.Continuity on the Management Board: Gerresheimer extends contract with CFO Dr. Bernd Metzner ahead of schedule by a further five years Duesseldorf, September 9, 2021 - At its most recent meeting, the Supervisory Board of Gerresheimer AG prematurely extended the contract of Chief Financial Officer Dr. Bernd Metzner (50) by a further five years until

  • EQS Group

    Gerresheimer AG: Gerresheimer accelerates revenue growth

    DGAP-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement/Half Year Report13.07.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Gerresheimer accelerates revenue growth Organic Group revenue growth of 7.5 %, and 7.1 % in core business Solutions for biotech drugs and high-value solutions continue to drive revenues increase Organic adjusted EBITDA margin at 22.8 % in core business Adjusted earnings per share up organically by 19.1 % to EUR 1.28 Guida